SG123531A1 - A method for the high level expression of active lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification - Google Patents

A method for the high level expression of active lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification

Info

Publication number
SG123531A1
SG123531A1 SG200200026A SG200200026A SG123531A1 SG 123531 A1 SG123531 A1 SG 123531A1 SG 200200026 A SG200200026 A SG 200200026A SG 200200026 A SG200200026 A SG 200200026A SG 123531 A1 SG123531 A1 SG 123531A1
Authority
SG
Singapore
Prior art keywords
purification
high level
level expression
chimeric proteins
beta receptor
Prior art date
Application number
SG200200026A
Other languages
English (en)
Inventor
Jeffrey Browning
Konrad Miatkowski
Werner Meier
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22345666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG123531(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of SG123531A1 publication Critical patent/SG123531A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
SG200200026A 1998-12-17 1999-12-16 A method for the high level expression of active lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification SG123531A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11275298P 1998-12-17 1998-12-17

Publications (1)

Publication Number Publication Date
SG123531A1 true SG123531A1 (en) 2006-07-26

Family

ID=22345666

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200200026A SG123531A1 (en) 1998-12-17 1999-12-16 A method for the high level expression of active lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification

Country Status (27)

Country Link
US (3) US7585946B2 (ru)
EP (3) EP2374872B2 (ru)
JP (4) JP4878676B2 (ru)
KR (3) KR100732934B1 (ru)
CN (2) CN101289512A (ru)
AT (1) ATE536372T1 (ru)
AU (2) AU777232B2 (ru)
BR (1) BR9916325B1 (ru)
CA (1) CA2354539A1 (ru)
CY (1) CY1117003T1 (ru)
CZ (1) CZ20012156A3 (ru)
DK (2) DK1141248T3 (ru)
EA (1) EA005270B1 (ru)
EE (1) EE200100324A (ru)
ES (1) ES2554482T5 (ru)
HK (2) HK1038244A1 (ru)
HU (1) HUP0200064A2 (ru)
IL (3) IL143670A0 (ru)
IS (1) IS5959A (ru)
NO (1) NO20012991L (ru)
NZ (3) NZ529276A (ru)
PT (1) PT2374872E (ru)
SG (1) SG123531A1 (ru)
SI (1) SI2374872T2 (ru)
SK (1) SK8552001A3 (ru)
TR (2) TR200504220T2 (ru)
WO (1) WO2000036092A2 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
PT1119370E (pt) * 1998-10-09 2006-09-29 Univ Emory Inversao do estado de choque sistemico e de dificuldade respiratoria originado por inducao viral por meio do bloqueio da via da linfotoxina beta
US7951378B2 (en) 2000-04-28 2011-05-31 Planet Biotechnology Inc. Immunoadhesin comprising a chimeric ICAM-1 molecule produced in a plant
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
AU2002245272B2 (en) * 2001-01-16 2006-06-29 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
AU2003299984A1 (en) * 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
MXPA05006522A (es) 2002-12-23 2006-02-17 Bristol Myers Squibb Co Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
EP1575998A4 (en) 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
WO2005024012A1 (en) * 2003-09-11 2005-03-17 Novozymes A/S Increased expression of a modified polypeptide
JP2008504009A (ja) * 2003-12-23 2008-02-14 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 腫瘍壊死因子結合蛋白質を生産する方法
US20110038854A1 (en) * 2006-03-30 2011-02-17 University Of Medicine And Dentistry Of New Jersey Strategy for homo- or hetero-dimerization of various proteins in solution and in cell
TWI414531B (zh) * 2006-10-12 2013-11-11 Genentech Inc 淋巴毒素α之抗體
US8067375B2 (en) * 2006-10-20 2011-11-29 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2139509A2 (en) * 2007-03-15 2010-01-06 Biogen Idec MA, Inc. Treatment of autoimmune disorders
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20110129468A1 (en) * 2008-02-29 2011-06-02 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CA2795461C (en) 2010-04-26 2018-04-24 Novartis Ag Improved cell cultivation process
WO2012176158A1 (en) * 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification of chimeric protein
JP6223338B2 (ja) * 2011-08-17 2017-11-01 アレス トレーディング ソシエテ アノニム 活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法
ES2633960T3 (es) 2012-10-15 2017-09-26 Bristol-Myers Squibb Company Procesos de cultivo de células de mamífero para la producción de proteínas
TWI745610B (zh) 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
IL297395B2 (en) 2015-06-30 2024-01-01 Pfizer Agonists for BTLA fusion proteins and uses thereof
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
CN105400721A (zh) * 2015-12-11 2016-03-16 湖南农业大学 一种快速筛选具有抗菌活性芽孢杆菌的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5447851A (en) * 1992-04-02 1995-09-05 Board Of Regents, The University Of Texas System DNA encoding a chimeric polypeptide comprising the extracellular domain of TNF receptor fused to IgG, vectors, and host cells
WO1998025967A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906096A (en) 1953-12-14 1959-09-29 Pacific Ind Mfg Co Precision control system for press brakes or the like
JP2810744B2 (ja) † 1989-07-04 1998-10-15 ノボ ノルディスク アクティーゼルスカブ Ｆ▲ｖｉｉｉ▼活性を有する蛋白質および／またはｆ▲ｖｉｉｉ▼誘導体の製造法
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
ES2157889T3 (es) * 1990-06-27 2001-09-01 Biogen Inc Linfotoxina complejada de superficie.
US5795964A (en) * 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
DK0585287T3 (da) † 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
NZ240718A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin analogues carrying mutations in the alpha-helix-1 region
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
WO1994006478A1 (en) 1992-09-22 1994-03-31 Medin Corporation A system for securing medical tools for sterilization
ATE199392T1 (de) † 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5726039A (en) * 1994-07-21 1998-03-10 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Vectors and transformed host cells for recombinant protein production at reduced temperatures
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
TR199802238T2 (xx) * 1996-05-08 1999-02-22 F. Hoffmann-La Roche Ag Astımın TNFR-Ig ile tedavisi.
US6040560A (en) * 1996-10-22 2000-03-21 Philip Morris Incorporated Power controller and method of operating an electrical smoking system
EE05213B1 (et) * 1996-10-25 2009-10-15 Biogen, Incorporated Lmfotoksiin- β retseptori (LT- β-R) blokeeriva agensi kasutamine ja LT- β-R-i blokeerivat agensit ning CD40L-i blokeerivat agensit sisaldav farmatseutiline kompositsioon
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
WO1998018824A1 (en) 1996-10-30 1998-05-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
US6221608B1 (en) * 1997-01-22 2001-04-24 Ortho Pharmaceutical Corporation Methods for identifying erythropoietin receptor binding protein
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
JP2002511264A (ja) * 1998-04-16 2002-04-16 ジェネンテック・インコーポレーテッド 組織プラスミノーゲン活性化因子プロ配列を使用するグリコシル化タンパク質の分泌
DE69929198T2 (de) † 1998-05-29 2006-08-10 Genentech, Inc., South San Francisco Zellkulturverfahren für die produktion von glycoproteinen
PT1119370E (pt) * 1998-10-09 2006-09-29 Univ Emory Inversao do estado de choque sistemico e de dificuldade respiratoria originado por inducao viral por meio do bloqueio da via da linfotoxina beta
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US9086881B2 (en) 2012-06-29 2015-07-21 Intel Corporation Mechanism for facilitating write tracking for following data eye movements across changing thermal conditions in memory systems

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447851A (en) * 1992-04-02 1995-09-05 Board Of Regents, The University Of Texas System DNA encoding a chimeric polypeptide comprising the extracellular domain of TNF receptor fused to IgG, vectors, and host cells
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
WO1998025967A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, NOVEMBER 1997, VOL. 63, NO. 11. *
JOURNAL OF IMMUNOLOGY, 1997 *

Also Published As

Publication number Publication date
EA200100670A1 (ru) 2001-12-24
DK2374872T4 (en) 2019-04-23
KR100732934B1 (ko) 2007-06-29
EP2374872A2 (en) 2011-10-12
CN101289512A (zh) 2008-10-22
KR20060084860A (ko) 2006-07-25
CA2354539A1 (en) 2000-06-22
CY1117003T1 (el) 2017-04-05
JP2014239697A (ja) 2014-12-25
US20020039580A1 (en) 2002-04-04
DK2374872T3 (en) 2015-12-14
KR20020013482A (ko) 2002-02-20
PT2374872E (pt) 2015-12-09
EA005270B1 (ru) 2004-12-30
TR200504220T2 (tr) 2007-04-24
AU2005200042B2 (en) 2008-05-01
AU2005200042A1 (en) 2005-02-03
IS5959A (is) 2001-05-31
SK8552001A3 (en) 2001-12-03
EP3006563A1 (en) 2016-04-13
IL143670A0 (en) 2002-04-21
BR9916325B1 (pt) 2011-06-28
WO2000036092A9 (en) 2002-08-22
NZ538599A (en) 2007-11-30
NZ529276A (en) 2005-03-24
HK1223398A1 (zh) 2017-07-28
SI2374872T2 (sl) 2019-05-31
JP5777171B2 (ja) 2015-09-09
HUP0200064A2 (en) 2002-05-29
ES2554482T3 (es) 2015-12-21
IL205698A (en) 2015-11-30
US20100136625A1 (en) 2010-06-03
EP1141248A2 (en) 2001-10-10
WO2000036092A2 (en) 2000-06-22
EP1141248B1 (en) 2011-12-07
DK1141248T3 (da) 2012-03-12
TR200101703T2 (tr) 2002-05-21
EP2374872B1 (en) 2015-11-25
US8283138B2 (en) 2012-10-09
CN1333819A (zh) 2002-01-30
KR20070091227A (ko) 2007-09-07
US7585946B2 (en) 2009-09-08
AU2364400A (en) 2000-07-03
JP4878676B2 (ja) 2012-02-15
HK1038244A1 (en) 2002-03-08
NZ549623A (en) 2008-05-30
ES2554482T5 (es) 2019-07-18
PL348816A1 (en) 2002-06-17
NO20012991L (no) 2001-08-17
SI2374872T1 (sl) 2016-03-31
BR9916325A (pt) 2001-10-02
EP2374872B2 (en) 2019-02-20
US8709759B2 (en) 2014-04-29
IL229738A0 (en) 2014-01-30
ATE536372T1 (de) 2011-12-15
CN100387708C (zh) 2008-05-14
WO2000036092A3 (en) 2000-11-23
EP2374872A3 (en) 2011-10-19
CZ20012156A3 (cs) 2001-09-12
US20130196376A1 (en) 2013-08-01
JP2010158252A (ja) 2010-07-22
NO20012991D0 (no) 2001-06-15
JP2013116118A (ja) 2013-06-13
JP2003517277A (ja) 2003-05-27
AU777232B2 (en) 2004-10-07
EE200100324A (et) 2002-10-15

Similar Documents

Publication Publication Date Title
SG123531A1 (en) A method for the high level expression of active lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification
FI964308A0 (fi) Radioresurssien käyt¦n ohjausmenetelmä
PL344520A1 (en) Method for purifying aliphatic aminonitriles
ZA979599B (en) Humanized anti-CD11a antibodies
PT939767E (pt) Factor viii porcino e seus hibridos
NO990514D0 (no) FremgangsmÕte og innretning for sveising med sveisestrÕlekontroll
EP0685199A3 (en) Method for analyzing an enzyme and device for its implementation.
EE9600015A (et) Meetod ja seade pehmete bioloogiliste kudede omavõnkumise registreerimiseks - müomeeter
NO975293D0 (no) Fremgangsmåte for mottaking, samt mottaker
AU5740698A (en) Welding system and method of determining the welding parameters for a welding current source
AP9901607A0 (en) Method and apparatus for continuous flow isoelectric focusing for
ZA985026B (en) Method for enhancing the activity of an enzyme.
IL115605A (en) Method for purifying keratinocyte growth factors
ATA64095A (de) Steuerungsverfahren für roboter, unter verwendung von geometrischen zwangsbedingungen und zufalls-suchverfahren
ZA988025B (en) Method for enhancing the activity of an enzyme.
FR2701953B1 (fr) Protéine de fusion multi-VIP et procédé de préparation de VIP recombinant.
IT1285726B1 (it) Metodo per il controllo dei rifornimenti di carburante e relativa apparecchiatura.
EP0693682A3 (de) Verfahren zur Bestimmung der Konzentration c eines in einer Trägersubstanz homogen verteilten Absorbens
DE69836971D1 (de) Methode und apparat zur vorhersage von funktionellen proteindomänen, methode zur verbesserung der proteinfunktion, sowie funktionell verbessertes protein
EP0679888A3 (en) Method for determining the ability to generate growth activity.
BR9605319A (pt) Estação de controle biológico
KR970006778A (ko) 콜드Co테스트에 대한 피드백제어방법
ZA979101B (en) Method of determining suspension movement.
FI101683B (fi) Menetelmä tuhkan rakeistamiseksi
ITPD950114A0 (it) Metodo per il controllo automatico di ricevitori radio-televisivi